Current Liabilities
Deferred Revenue
West Pharmaceutical Services Deferred Revenue decreased by 11.6% to $3.80M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2018
Last reportedQ1 2026
How to read this metric
An increase is generally positive, signaling strong future demand and cash collection, while a decrease indicates the fulfillment of obligations.
Detailed definition
This represents payments received from customers for goods or services that have not yet been delivered or performed. It...
Peer comparison
Common in subscription and long-term contract businesses; highly indicative of future revenue visibility.
Metric ID:
deferred_revenue_currentHistorical Data
4 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|
| Value | $3.10M | $2.80M | $4.30M | $3.80M |
| QoQ Change | — | -9.7% | +53.6% | -11.6% |
| YoY Change | — | — | — | +22.6% |
Range$2.80M – $4.30M
Avg YoY Growth+22.6%
Median YoY Growth+22.6%
Product Breakdown
| Segment | Q4 '21 |
|---|---|
| Smart Dose | $900.00K |
| Total | — |
Deferred Revenue at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's deferred revenue?
- West Pharmaceutical Services (WST) reported deferred revenue of $3.80M in Q1 2026.
- What does deferred revenue mean?
- Cash received from customers for work that has not yet been completed.